Search results for: "Novo Nordisk"

(283 records)

Research & Development
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline...
Regulatory
MHRA approves first oral semaglutide tablet for weight loss in the UK

MHRA approves first oral semaglutide tablet for weight loss in the UK

Novo Nordisk's Wegovy tablet becomes the UK's first GLP-1 receptor agonist in oral form for obesity treatment — a significant shift in delivery format as the drug awaits NICE...
Finance
Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected...
Pharma 5.0
Novo Nordisk and OpenAI partner to accelerate drug discovery with AI integration

Novo Nordisk and OpenAI partner to accelerate drug discovery with AI integration

The Wegovy and Ozempic maker has struck a strategic deal with OpenAI to embed artificial intelligence across its entire operations, with full integration targeted by the end of...
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or...
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a...
Pharmaceutical
Novo Nordisk and Hims end GLP-1 spat, strike deal to sell Wegovy and Ozempic

Novo Nordisk and Hims end GLP-1 spat, strike deal to sell Wegovy and Ozempic

The pair have reached an agreement under which the telehealth company can sell Novo's Ozempic and Wegovy, ending a legal dispute that flared last month
Manufacturing
Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

The company is preparing to scale production capacity at its Athlone facility as strong US uptake of its oral obesity therapy supports a broader strategy to expand global...
Regulatory
Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Drug Delivery
Indonesia looks to oral GLP-1s as it battles rising obesity

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction...
Finance
Global consortium launches to accelerate antibiotic discovery

Global consortium launches to accelerate antibiotic discovery

The $60m consortium backed by the Gates Foundation, Novo Nordisk Foundation and Wellcome aims to speed the discovery of next-generation antibiotics to tackle the growing threat...
Finance
Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into...
Pharmaceutical
Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Regulatory
Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court

The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign...
Research & Development
A new era in diabetes: five biotech companies moving past daily insulin injections

A new era in diabetes: five biotech companies moving past daily insulin injections

From cell-encapsulation platforms and islet transplantation breakthroughs to next-generation GLP-1 combinations and connected insulin delivery, a new wave of biotech innovation...
Media
Alzheimer's Association comments on failed Novo Nordisk GLP-1 trial

Alzheimer's Association comments on failed Novo Nordisk GLP-1 trial

The company said the results from the evoke study, which tested an oral semaglutide pill for early-stage symptomatic Alzheimer's disease, were "not what we had hoped for"

Trending Articles

  1. Nicox’s NCX 470 new drug application submitted in the United States by Kowa The submission is based on positive results from two Phase III clinical trials (Mont Blanc and Denali)
  2. Thermo Fisher's Patheon becomes exclusive third-party CDMO for KinetiSol technology The agreement will install KinetiSol Formulator equipment across Patheon's Bend and Cincinnati OSD sites, offering pharma customers an integrated development-to-commercial pathway for poorly soluble drug candidates
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Annex 1 at the transfer point: how to meet the evolving evidence challenge As Annex 1 raises expectations for contamination control, transfer-point evidence must become more dynamic, connected and defensible throughout the entire product lifecycle
  4. Sanofi offers EU commitments for flu vaccine disparagement claims Sanofi has proposed remedies to EU antitrust regulators after allegations it disparaged rival CSL Seqirus's Fluad vaccine in Germany and France since 2024
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Back to basics: a simple guide to checkweighing in pharmaceutical production Mettler-Toledo’s Miriam Krechlok tells Dr Kevin Robinson how checkweighing helps pharmaceutical manufacturers to verify product completeness, control fill levels and maintain compliance, safety and efficiency

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Digital The AI-driven biotech and China Medical System have struck a second collaboration in three months, targeting a mass-market CNS indication via a novel mechanism identified by...
Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Read more
Research & Development The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline...
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Read more
Manufacturing Piramal Pharma Limited (PPL) (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a...
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Read more
Manufacturing The FDA's pre-licence inspection approval of WuXi Biologics' MFG8 facility will strengthen the CRDMO's commercial manufacturing network, supporting the global supply of a...
WuXi Biologics' Hebei facility secures FDA PLI approval for commercial autoimmune biologics manufacturing

WuXi Biologics' Hebei facility secures FDA PLI approval for commercial autoimmune biologics manufacturing

Read more
Manufacturing Boehringer Ingelheim has selected the osapiens HUB for Mobile Maintenance for its global, regulated manufacturing operations
Boehringer Ingelheim standardises plant maintenance globally with osapiens

Boehringer Ingelheim standardises plant maintenance globally with osapiens

Read more
Manufacturing With throughput up to 100 kg/h, the new twin-screw extruder brings lab-grade process understanding into pilot-scale production, enabling users to validate process parameters...
Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Read more
Dosage Forms While injection pens and weight-loss pills are gaining ground across the Western world, the debate focuses one-sidedly on the kilos and not on the body’s health and the...
Obesity medication: fast results … but at the expense of long-term health

Obesity medication: fast results … but at the expense of long-term health

Read more
Pharmaceutical The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar...
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Read more